The Relationship Between Gait Task Performance and Plasma Biomarkers for Alzheimer’s Disease in Cognitively Unimpaired Older Adults and Patients with Mild Cognitive Impairment

Authors:
  • JSJordan Sergio
    Jordan Sergio
  • PSPeter Snyder
    Peter Snyder
  • SDSavannah Doster
    Savannah Doster
  • MDMaeve Durkin
    Maeve Durkin
  • JSJennifer Strenger
    Jennifer Strenger
  • LTLouisa Thompson
    Louisa Thompson
  • MSMegan Stradtman
    Megan Stradtman
  • SSStuart Sinoff
    Stuart Sinoff

Abstract
The Timed Up and Go (TUG) is a 20-foot gait assessment, with TUG-dual task (DT) serial subtractions to determine dual-task cost. Alzheimer’s disease (AD) risk is established using plasma biomarkers and APOE genotyping. We investigated: 1) TUG/TUG-DT differences between AD low-risk cognitively unimpaired (CU) older adults (N = 74), AD high-risk CU older adults (N = 87), and mild cognitively impaired (MCI) older adults (N = 33) and 2) the relationship between TUG/TUG-DT performance and plasma biomarkers. One hundred and ninety-four older adults ages 55–80 completed TUG/TUG-DT, a fasting blood draw, and APOE genotyping. Scores on the Clinical Dementia Rating Scale (CU = 0; CI = ≥0.5) and Montreal Cognitive Assessment (CU ≥ 24; CI = ≤23) determined whether participants were placed into the CU low-risk, CU high-risk, or MCI groups. Risk level for CU participants were assessed by APOE genotyping. Those participants who carried at least one copy of the APOE ε4 allele were designated to the high-risk group (n = 87). Participants with no APOE ε4 allele were assigned to the low-risk group (n = 75). MCI participants took longer to perform the TUG than CU participants (p < 0.001). CU high-risk and MCI group performed similarly on step counts, while the CU low-risk took significantly fewer steps (p<0.001). Speed predicted whether someone was below an AD-risk threshold for pTau217 in CU participants (n = 150). Exploratory generalized additive models showed plasma biomarkers predicted gait metrics in CU groups. Step count may be more sensitive, compared to speed alone, in identifying those in preclinical AD stages. Gait metrics (speed and efficiency) played a key role as a clinical manifestation of early AD pathophysiology determined by blood-based biomarker concentration. Combining these assessments offers a multidimensional, cost-effective approach for preclinical-AD screening and potential early intervention.